DPP4 and type 2 diabetes mellitus: DPP-4 inhibitors (DPP-4i) are oral glucose-lowering medications approved for the treatment of T2D due to their ability to improve glucose control by extending the half-life and biological activity of endogenous GLP-1 and GIP [113,114].